<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920303-0133</DOCNO><DOCID>920303-0133.</DOCID><HL>   CellPro to Begin Human Trial</HL><DATE>03/03/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   CPRO</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>SCIENCE andamp; TECHNOLOGY (SCN)</NS><GV>HEALTH AND HUMAN SERVICES (HHS)</GV><RE>NORTH AMERICA (NME)PACIFIC RIM (PRM)UNITED STATES (US)WASHINGTON (WA)</RE><LP>   BOTHELL, Wash. -- CellPro Inc. said it would initiate ahuman clinical trial in gene therapy using stem cells underan agreement with the National Heart, Lung and BloodInstitute of the National Institutes of Health.   The trial will begin by treating patients with severecombined immunodeficiency or SCID, a congenital immunedisorder, the biotechnology concern said. CellPro said it isthe first gene therapy study to utilize concentrated stemcells -- which are present in bone marrow and blood -- ratherthan white blood cells.</LP><TEXT/></DOC>